Guggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price Target

While Opus Genetics, Inc. (NASDAQ:IRD) has gained 100.50% year-to-date, analysts continue to see 148.10% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy.

Fresh coverage initiations and a series of positive data readouts have kept analyst attention firmly on this clinical-stage gene therapy company.

On June 4, 2026, Guggenheim initiated coverage of Opus Genetics, Inc. (NASDAQ:IRD) with a “Buy” rating and a $16 price target, the most bullish call among covering analysts.

That followed Leerink’s initiation on May 21, 2026, with an “Outperform” rating and a $10 price target. Leerink described Opus Genetics, Inc. (NASDAQ:IRD) as a clinical-stage company developing gene therapies for inherited retinal disorders and called the first patient data for OPGxBEST1 “encouraging,” pointing to a market opportunity Opus estimates at up to $9 billion.

The firm said even conservative projections for OPGxLCA5 and OPGxBEST1 support a compelling risk/reward profile and believes Opus Genetics, Inc. (NASDAQ:IRD) is well capitalized for its commercial-stage transition.

Meanwhile, on May 13, 2026, Citizens trimmed its price target on Opus Genetics, Inc. (NASDAQ:IRD) to $11 from $12 while keeping an “Outperform” rating. The firm noted that recent ARVO data continue to support OPGx-LCA5’s durable efficacy and favorable safety profile, with pediatric results aligning with adult outcomes. FDA Rare Disease Endpoint Pathway acceptance and a manageable pivotal study design were cited as meaningful de-risking factors, with upcoming September data from the BEST1 study flagged as the next key catalyst.

Broader analyst sentiment, meanwhile, remains firmly positive. Seventeen analysts cover the stock with bullish ratings and a consensus mean price target of $10.00.

Opus Genetics, Inc. (NASDAQ:IRD) is engaged in the research and development of ophthalmic biopharmaceutical products, with a focus on developing and commercializing therapies for several eye disorders.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.